Compare · CMMB vs IVA
CMMB vs IVA
Side-by-side comparison of Chemomab Therapeutics Ltd. (CMMB) and Inventiva S.A. (IVA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CMMB and IVA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- IVA is the larger of the two at $1.11B, about 66.5x CMMB ($16.7M).
- CMMB has hit the wire 2 times in the past 4 weeks while IVA has been quiet.
- IVA has more recent analyst coverage (17 ratings vs 5 for CMMB).
- Company
- Chemomab Therapeutics Ltd.
- Inventiva S.A.
- Price
- -
- -
- Market cap
- $16.7M
- $1.11B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 2
- 0
- Recent ratings
- 5
- 17
Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd. engages in the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 16, 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
Inventiva S.A.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
Latest CMMB
- SEC Form 6-K filed by Chemomab Therapeutics Ltd.
- Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form SCHEDULE 13D filed by Chemomab Therapeutics Ltd.
- Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis
- SEC Form 6-K filed by Chemomab Therapeutics Ltd.
- SEC Form 3 filed by new insider Melincoff Gwen A
- SEC Form 6-K filed by Chemomab Therapeutics Ltd.
- Chief Executive Officer Mor George Adi disposed of 50,462 units of American Depositary Shares, decreasing direct ownership by 87% to 18,750 units (SEC Form 4)
- SEC Form 6-K filed by Chemomab Therapeutics Ltd.
- Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
Latest IVA
- Amendment: SEC Form 6-K/A filed by Inventiva S.A.
- Correction: Inventiva Announces Preliminary Financial Results for the First Half of 2026¹
- SEC Form 6-K filed by Inventiva S.A.
- Inventiva Announces Preliminary Financial Results for the First Half of 2026¹
- Cantor Fitzgerald initiated coverage on Inventiva
- SEC Form 6-K filed by Inventiva S.A.
- Inventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB Warrants
- SEC Form 6-K filed by Inventiva S.A.
- Results of the Votes of the Combined Shareholders’ General Meeting of June 30, 2026
- Claret Capital Partners participates in €130m financing for Inventiva